Darrel Ornelle ELION ASSIANA

Dr. Darrel Ornelle ELION ASSIANA

Faculté des Sciences et Techniques, Marien Ngouabi University, Brazzaville, Congo
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Emerging Infectious Diseases
Verified
Journal Article
Open access
JMJean-Vivien Mombouli
Jean-Vivien Mombouli
PBPatrick Bitsindou
Patrick Bitsindou
Darrel Ornelle ELION ASSIANADarrel Ornelle ELION ASSIANA
Darrel Ornelle ELION ASSIANA
AGAllen Grolla
Allen Grolla
HFHeinz Feldmann
Heinz Feldmann
VMVincent Munster
Vincent Munster

17 December 2021 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
Darrel Ornelle ELION ASSIANADarrel Ornelle ELION ASSIANA
Darrel Ornelle ELION ASSIANA
JAJabar Babatunde Pacôme Achimi Abdul
Jabar Babatunde Pacôme Achimi Abdul
LLLaure Stella Ghoma Linguissi
Laure Stella Ghoma Linguissi
MEMicheska Epola
Micheska Epola
JVJeannhey Christevy Vouvoungui
Jeannhey Christevy Vouvoungui
FNFrancine Ntoumi
Francine Ntoumi
Background: There is paucity of data on the prevalence and distribution of multidrug- Resistant-Tuberculosis (MDR-TB) in the Republic of Congo. Among the challenges resides the implementation of a robust TB resistance diagnostic program using molecular tools. In resource limited settings there is a need to gather data to enable prioritization of actions. The objective of this study was is to implement molecular tools as a best of diagnosing MDR and XDR-TB among presumptive tuberculosis patients referred to reference hospital of Makelekele in Brazzaville, Republic of the Congo. Methods: We have conducted a cross-sectional study, including a total of 92 presumptive pulmonary tuberculosis patients and who had never received treatment recruited at the reference hospital of Makelekele from October 2018 to October 2019. The socio-demographic and clinical data were collected as well as sputum samples. Rifampicin resistance was investigated using Xpert (Cepheid) and second-line TB drugs Susceptibility testing were performed by the Brucker HAIN Line Probe Assay (GenoType MTBDRsl VER 2.0 assay) method. Results: From the 92 recruited patients, 57 (62%) were found positive for the Mycobacterium tuberculosis complex. The prevalence of rifampicin-resistant tuberculosis (RR-TB) was 9.8% (9/92) and importantly 2.2% were pre-XDR/XDR. Conclusion: This study showed a high rate of rifampicin resistance and the presence of extensively drug-resistant tuberculosis in the study area in new patients. This study highlights the need for further studies of TB drug resistance in the country.

9 May 2025 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
BNBreli Bonheur Ngouama
Breli Bonheur Ngouama
JDJean Claude Djontu
Jean Claude Djontu
Darrel Ornelle ELION ASSIANADarrel Ornelle ELION ASSIANA
Darrel Ornelle ELION ASSIANA
FMFreisnel Hermeland Mouzinga
Freisnel Hermeland Mouzinga
MDMita Naomie Merveille Dello
Mita Naomie Merveille Dello
FNFrancine Ntoumi
Francine Ntoumi
Background: WHO strategy to end Tuberculosis (TB) calls for drug susceptibility testing of Mycobacterium tuberculosis (MTB) for all patients, in high TB burden settings. Thus, this study aimed to investigate the MTB drug resistance profiles and related risk factors among patients presenting to the Antituberculosis Center of Brazzaville, Republic of Congo. Methods: A cross-sectional study was carried out from July 2022 to August 2023 involving 1,121 presumptive pulmonary tuberculosis patients enrolled to the Antituberculosis Center of Brazzaville. Sputum samples were collected from all the study participants for the diagnosis of tuberculosis and rifampicin resistance, using the Xpert MTB/RIF (Cepheid, USA) assay. Samples positive for MTB with drug resistance to RIF were further tested for the second line anti-MTB drug susceptibility using the 10-color Xpert MTB/XDR assay. Result: Out of 1,121 presumptive TB patients tested, 302/1,121 (26.9%) were MTB positive. Among these, 18/302 (6.0%) had received previous TB treatment and 15/302 (5.0%) were HIV co-infected. The mean age of the study population was 34 years, with a higher prevalence in males (69.2%). Of the MTB isolates, 25/302 (8.3%) were Rifampicin-resistant, with 24/25 (96%) further confirmed as multi-resistant strains, including 6/24 (25%) pre-XDR. Risk factors for MDR-TB included a history of TB treatment (AOR = 8.96, p = 0.002) and chronic cough (AOR = 7.14, p = 0.003). Conclusions: This study reveals a high level of drug-resistant tuberculosis in Brazzaville, with previous TB treatment being a significant risk factor. The findings underscore the need to strengthen molecular surveillance and TB management and control measures in the Republic of Congo.

12 December 2022 in BMC Public Health
Verified
Journal Article
Open access
PDF file
VEViny Andzi Elenga
Viny Andzi Elenga
Abel LissomAbel Lissom
Abel Lissom
Darrel Ornelle ELION ASSIANADarrel Ornelle ELION ASSIANA
Darrel Ornelle ELION ASSIANA
JVJeannhey Christevy Vouvoungui
Jeannhey Christevy Vouvoungui
DCDjontu Jean Claude Jean Claude
Djontu Jean Claude Jean Claude
FNFrancine Ntoumi
Francine Ntoumi
Human African trypanosomiasis (HAT) is one of the world’s classical neglected tropical diseases representing a major public health threat in sub-Saharan Africa. Although the parasitic disease is in decline in the Republic of Congo, the better understanding of the epidemiological situation of active foci is required to reduce the risk of disease resurgence which could impede progress registered so far. The aim of this study was to determine the prevalence of HAT and the associated risk factors in individuals living in remote areas of the Republic of Congo. A cross-sectional survey was carried out in volunteers living in rural settings from June 2020 to January 2021. Socio-demographic and Clinical parameters of the participants were recorded. The presence of HAT-specific antibodies was assessed in whole blood, and then confirmed in serial diluted plasma samples using Card-Agglutination Trypanosomiasis Test (CATT)/T.b. gambiense CATT. The Capillary Tube Centrifugation (CTC) and Lymph nodes (LN) examination were done for detecting trypanosome parasites in CATT-serum positive cases. The staging of positive participants was determined by cerebrospinal fluid (CSF) examination. Out of 8556 enrolled participants, 48.5% were more than 15 years old, 57.7% were unschooled and 67.2% practiced peasant activities. The prevalence of HAT infection was 0.3% with the predominance of patients at stage 1 of the disease (84.0%). The districts of Mindouli (OR: 25.9 (5.2–468); p = 0.0016) and Mpouya (OR: 13.3 (2.5–246); p = 0.0140) was revealed as the foci of high risk of HAT infection. Several factors were associated with an increased risk of HAT infection mainly including the non-schooling (OR: 5.1 (1.2–21.9); p = 0.0268), the life in couple or married (OR: 3.3 (1.0–11.3); p = 0.0545) and the practice of peasant activities (OR: 6.9 (2.4–29.3); p = 0.0017). This study highlights the need of revising and strengthening the strategies of HAT control in Republic of Congo, using an approach which will take into account the education level, the marital status and the occupation of the population at risk.

1 March 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
SPSrinivas Pallerla
Srinivas Pallerla
Darrel Ornelle ELION ASSIANADarrel Ornelle ELION ASSIANA
Darrel Ornelle ELION ASSIANA
LLLe Thi Kieu Linh
Le Thi Kieu Linh
FCFrederick Nchang Cho
Frederick Nchang Cho
CMChristian Meyer
Christian Meyer
Thirumalaisamy P. VelavanThirumalaisamy P. Velavan
Thirumalaisamy P. Velavan
HIV-infection, tuberculosis and malaria are the big three communicable diseases that plague sub-Saharan Africa. If these diseases occur as co-morbidities they require polypharmacy, which may lead to severe drug-drug-gene interactions and variation in adverse drug reactions, but also in treatment outcomes. Polymorphisms in genes encoding drug-metabolizing enzymes are the major cause of these variations, but such polymorphisms may support the prediction of drug efficacy and toxicity. There is little information on allele frequencies of pharmacogenetic variants of enzymes involved in the metabolism of drugs used to treat HIV-infection, TB and malaria in the Republic of Congo (ROC). The aim of this study was therefore to investigate the occurrence and allele frequencies of 32 pharmacogenetic variants localized in absorption distribution, metabolism and excretion (ADME) and non-ADME genes and to compare the frequencies with population data of Africans and non-Africans derived from the 1000 Genomes Project. We found significant differences in the allele frequencies of many of the variants when comparing the findings from ROC with those of non-African populations. On the other hand, only a few variants showed significant differences in their allele frequencies when comparing ROC with other African populations. In addition, considerable differences in the allele frequencies of the pharmacogenetic variants among the African populations were observed. The findings contribute to the understanding of pharmacogenetic variants involved in the metabolism of drugs used to treat HIV-infection, TB and malaria in ROC and their diversity in different populations. Such knowledge helps to predict drug efficacy, toxicity and ADRs and to inform individual and population-based decisions.

15 April 2025 in IJID Regions
Verified
Journal Article
Open access
BNBreli Bonheur Ngouama
Breli Bonheur Ngouama
FMFreisnel Hermeland MOUZINGA
Freisnel Hermeland MOUZINGA
MDMita Naomie Merveille Dello
Mita Naomie Merveille Dello
JDJean Claude Djontu
Jean Claude Djontu
Darrel Ornelle ELION ASSIANADarrel Ornelle ELION ASSIANA
Darrel Ornelle ELION ASSIANA
FNFrancine Ntoumi
Francine Ntoumi
Tuberculosis (TB) treatment outcome is one of the key indicators to evaluate the performance of TB control programs. This study aims to assess TB treatment outcomes and their related associated factors in patients treated at the Antituberculosis Center of Brazzaville, Republic of Congo. A prospective cohort study was conducted at the Antituberculosis Center of Brazzaville from July 2022 to August 2023, involving 305 patients with pulmonary TB diagnosed with the GenXpert MTB/RIF assay. These patients were closely monitored using acid-fast bacillus microscopy while receiving treatment based on whether they were drug-sensitive (DS) or drug-resistant. Sputum samples from patients who were DS were analyzed at 2, 5, and 6 months, whereas patients who were multi-drug–resistant (MDR) underwent a monthly sputum analysis for 9 months. The overall successful treatment rate was 80.3%, with 70.8% of patients cured and 9.5% completing treatment. Conversely, 19.7% experienced unsuccessful outcomes, including 13.4% loss to follow-up, 3.6% deaths, and 1.6% treatment failures. The treatment success in individuals co-infected with HIV was 46.7% (seven of 15), whereas it was 42% (eight in 19) in patients who were MDR. HIV-negative status (adjusted odds ratio = 5.11; 95% confidence interval: 1.73-13.44) and DS-TB (adjusted odds ratio = 8.29; 95% confidence interval: 3.17-21.04) were associated with increased success of treatment outcome. The overall TB treatment success rate was below the World Health Organization End TB Strategy threshold, with a high proportion of patients lost to follow-up and a low treatment success in patients with TB/HIV and those who were MDR. The findings highlight the need to enhance supervision, improve directly observed treatment short course monitoring, and develop strategies to minimize patients lost to follow-up.